deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 13-arm NCT02014558

Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Sponsor: Astellas Pharma Global Development, Inc.

Conditions Acute Myeloid Leukemia
Interventions Cephalexin Gilteritinib Midazolam Voriconazole
Updated 16 times since 2017 Last updated: Nov 7, 2024 Started: Oct 9, 2013 Primary completion: Aug 4, 2017 Completion: Mar 7, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Acute Myeloid Leukemia, this trial is completed. The trial is conducted by Astellas Pharma Global Development, Inc. and has accumulated 16 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Jun 2017 · 2 months · monthly snapshot~Jun 2017 – ~Nov 2017 · 5 months · monthly snapshot~Nov 2017 – ~May 2018 · 6 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Mar 2019 · 9 months · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~Jun 2019 · 2 months · monthly snapshot~Jun 2019 – ~Jan 2021 · 19 months · monthly snapshot~Jan 2021 – ~Jan 2022 · 12 months · monthly snapshot~Jan 2022 – ~Mar 2022 · 59 days · monthly snapshot~Mar 2022 – ~Jul 2024 · 28 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshot~Jan 2025 – present · 18 months · monthly snapshot

Change History

16 versions recorded

  1. Jan 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2024 — Jan 2025 [monthly]

    Completed PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Mar 2022 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  5. Jan 2022 — Mar 2022 [monthly]

    Completed PHASE1_PHASE2

▶ Show 11 earlier versions

  1. Jan 2021 — Jan 2022 [monthly]

    Completed PHASE1_PHASE2

  2. Jun 2019 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  3. Apr 2019 — Jun 2019 [monthly]

    Completed PHASE1_PHASE2

  4. Mar 2019 — Apr 2019 [monthly]

    Completed PHASE1_PHASE2

  5. Jun 2018 — Mar 2019 [monthly]

    Completed PHASE1_PHASE2

  6. May 2018 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  7. Nov 2017 — May 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  8. Jun 2017 — Nov 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  9. Apr 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  10. Feb 2017 — Apr 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  11. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    First recorded

Oct 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Astellas Pharma Global Development, Inc.
Data source: Astellas Pharma Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Berlin, Germany , Birmingham, United States , Bologna, Italy , Buffalo, United States , Charleston, United States , Chicago, United States , Cleveland, United States , Dresden, Germany , Duarte, United States and 12 more locations